Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive cancers, with a high mortality rate among patients. Previous findings have pointed to chitinase 3-like 1 (CHI3L1) as being behind PDAC resistance to gemcitabine, and thus a promising therapeutic target.
Immunovia AB significantly increased the accuracy of its test for the early detection of pancreatic cancer, achieving an 85% sensitivity and a specificity of 98%.
The disappointments continue for Fibrogen Inc., which is terminating work on its once-promising anti-CTGF monoclonal antibody, pamrevlumab, after reporting missed endpoints in two late-stage pancreatic cancer studies, and cutting its workforce by about 75%.
Researchers from Shanghai Jiao Tong University presented data from a study that aimed to assess the role of long intergenic non-protein coding RNA 1605 (LINC01605) in the progression of pancreatic ductal adenocarcinoma (PDAC).
Radiopharm Theranostics Ltd. announced a AU$70 million (US$46.69 million) institutional placement, and as part of that capital raise, radiopharma company Lantheus Holdings, Inc., has agreed to make an initial equity investment of AU$7.5 million.
Radiopharm Theranostics Ltd. announced a AU$70 million (US$46.69 million) institutional placement, and as part of that capital raise, radiopharma company Lantheus Holdings, Inc., has agreed to make an initial equity investment of AU$7.5 million.
Genfleet Therapeutics (Shanghai) Co. Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to advance GFH-375 (VS-7375) into a phase I/II study in patients with advanced solid tumors with KRAS G12D mutation.
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, in part due to the immunosuppression surrounding the tumor mediated by regulatory T cells (Tregs), thus preventing effective responses to immune therapy.
Mutations in GTPase KRAS occur in about 25% of human cancers, with the KRAS G12V mutation being one of the most frequent variants, and lead to activation of the MAPK pathway, thus promoting tumorigenesis.
Positive updated phase II data with CAN-2409 in pancreatic cancer led shares of Candel Therapeutics Inc. (NASDAQ:CADL) to close April 4 at $6.40, up $4.72, or 281%, well above the firm’s previous 52-week high. At one point during the day, the stock had climbed to $7.65.